EXPANDING YOUR REACH
A BRIDGE TO CHINA
To complement your drug and MD development and shorten the time to market in China, Opera acts as a bridge to China.
Our regulatory experts have years of experience with the NMPA and are familiar with the subtle differences in local regulatory requirements. They can provide you with feasible strategies and act as liaison with various regulatory agencies, both on technical and regulatory issues.
In this article, you will find a succint overview of 4 different strategies that pharmaceutical companies can apply if they are pursuing the approval of their drug product in China.
Learn more about entering the Chinese market with your product
A BRIEF INTRODUCTION OF TIGERMED
A global CRO with Chinese origins that is committed to supporting her clients in their clinical development in the best possible way.
Since Tigermed's inception in 2004, the company has always embraced new technologies and partnerships to accelerate product development and generate the clinical evidence its clients require to demonstrate real-world value.
2000+
Clinical Trials
5300+
Colleagues
300+
Innovative Drug Projects
130+
Service Locations
OFFERING SUPPORT THROUGHOUT THE PRODUCT LIFECYCLE
Tigermed’s core strengths lie in providing professional clinical development, R&D services, and value-adding solutions to support our life sciences clients, throughout the product lifecycle.
-
Clinical Operations
-
Regulatory Affairs
-
Integrated Technology
-
Biometrics
-
Real-World Data
-
Medical Devices
Navigating China's Market
Thanks to our partnership with Tigermed, we have all the resources to support biotech, pharmaceutical, and medical companies to enter the Chinese market.
NMPA Interaction
Our regulatory experts have years of experiences with the NMPA, China's Health Authority, and are familiar with the differences in local regulatory requirements.
Regulatory Strategy
Known as the 'Innovative CRO' in China, Tigermed has a history of providing the up-to-date intelligence that is essential for any regulatory strategy to enter the Chinese pharmaceutical market.
Local Expertise, Global Reach
The Tigermed Group has successfully supported thousands of companies in local trials and global projects and enabled them to provide solutions for unmet patient needs.
Clinical Trials in China
Tigermed's team has covered 57 cities across China with over 1000 professionals. Together, they have performed over 700 trials in more than 700 hospitals.
Medical Translations
Tigermed's team has covered 57 cities across China with over 1000 professionals. Together, they have performed over 700 trials in more than 700 hospitals.
OTHER TIGERMED
SOLUTIONS
Do you want to know more about China-related matters regarding Clinical Trials, Regulatory Affairs, Product Development, and the Chinese market landscape? Set up a call with one of our experts.
